DMT310-001 Topical in the Treatment of Acne Vulgaris

ClinicalTrials.gov ID: NCT03536637

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03536637. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study of Tolerability, Safety, And Efficacy, of DMT310 In Patients With Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

Study identification

NCT ID: NCT03536637
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Dermata Therapeutics; Industry
Enrollment: 121 participants

Conditions and interventions

Conditions

Acne Vulgaris

Interventions

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 22, 2018 (Actual)
Primary completion: Dec 30, 2018 (Actual)
Completion: Jan 28, 2019 (Actual)
Last update posted: Jul 22, 2020

2018 – 2019

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
Dermata Investigational Site	San Diego	California	92123	—
Dermata Investigational Site	Saint Joseph	Missouri	64506	—
Dermata Investigational Site	Henderson	Nevada	89148	—
Dermata Investigational Site	Albuquerque	New Mexico	87106	—
Dermata Investigational Site	High Point	North Carolina	27262	—
Dermata Investigational Site	Tennessee City	Tennessee	37215	—
Dermata Investigational Site	Austin	Texas	78759	—
Dermata Investigational Site	College Station	Texas	77802	—
Dermata Investigational Site	Katy	Texas	77494	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03536637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2020 · Synced Nov 12, 2026